CATAPRES
LOE ApproachingNDAORALTABLETPriority Review
Approved
Sep 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
CATAPRES by Boehringer Ingelheim is system structure and components catapres‑tts is a multi-layered film, 0. Approved for the treatment of hypertension. First approved in 1974.
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CATAPRES (clonidine) is an oral tablet antihypertensive agent approved in 1974 for the treatment of hypertension. It functions as a central-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system. The drug is delivered via a multi-layered transdermal or oral formulation depending on the specific product variant.
LOE Approaching
With LOE approaching, the brand team is likely focused on lifecycle extension strategies, pricing optimization, and managed decline; expect smaller, specialized commercial teams rather than expansion.
Mechanism of Action
System Structure and Components Catapres‑TTS is a multi-layered film, 0.2 mm thick, containing clonidine as the active agent. The system areas are 3.5 cm(Catapres‑TTS‑1), 7.0 cm (Catapres‑TTS‑2) and 10.5 cm (Catapres‑TTS‑3) and the amount of drug released is directly proportional to the area (see…
Indications (1)
Worked on CATAPRES at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.